Zoetis Inc. (ZTS)

Market Cap	79.26B
Revenue (ttm)	9.15B
Net Income (ttm)	2.43B
Shares Out	451.17M
EPS (ttm)	5.32
PE Ratio	33.04
Forward PE	28.54
Dividend	$1.73 (0.98%)
Ex-Dividend Date	Oct 31, 2024

Volume	1,846,901
Open	176.42
Previous Close	175.56
Day's Range	173.83 - 177.40
52-Week Range	144.80 - 201.92
Beta	0.90
Analysts	Strong Buy
Price Target	219.50 (+24.95%)
Earnings Date	Nov 4, 2024

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 14,100
• Stock Exchange: NYSE
• Ticker Symbol: ZTS
• Website: https://www.zoetis.com

Financial Performance

In 2023, Zoetis's revenue was $8.54 billion, an increase of 5.74% compared to the previous year's $8.08 billion. Earnings were $2.34 billion, an increase of 10.88%.

Analyst Forecast

According to 8 analysts, the average rating for ZTS stock is "Strong Buy." The 12-month stock price forecast is $219.5, which is an increase of 24.95% from the latest price.

Price Target

$219.5

(24.95% upside)

Analyst Consensus: Strong Buy